Business Wire

TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a patient ...
Business Wire

Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from UTILISE ...
Morningstar

New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk ...

New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for ...
Nasdaq

New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB ...

Study data also show that using certain DecisionDx-Melanoma test results in conjunction with current guidelines can reduce the number of SLNB procedures performed, particularly in patients with a low ...